Document:

Exhibit
10.32

 

	Advanced	 	 
	SOLUTIONS	 
	LIFE
    SCIENCES	 

 

An
Advanced Solutions, Inc. Company

 

Platform-as-a-Service

Biolife4D

 

Opportunity
#: OPP-0013290

 

December
20th, 2021

 

www
..advancedsolutions.com

 

    	 

     

    

 

		2017
                                            YPO

    Global

    Innovation

    Award
    Winner

 

New
York City, NY- May 12, 2017

 

YPO,
the premier chief executive leadership organization in the world, with 24,000 members across 130 countries, awarded Advanced Solutions
Life Sciences, LLC its 2017 Global Innovation Award for the BioAssemblyBot® Technology Platform.

 

YPO
Innovation Week (May 8-12, 2017) connected influential entrepreneurs, innovators and thought leaders to exchange ideas about inspiration,
breakthroughs and transformation through more than SO signature events, live two-way interactive video casts and livestream events around
the world. At the conclusion of the week, YPO announced the top Global Innovation Award winner in New York City.

 

2017
Global Innovation Award Recipient

 

Michael
Go/way, President and CEO of Advanced Solutions, Inc

 

Michael
Galway is the lead inventor of the BioAssemblyBot®, the world’s first 3D human tissue printer that uses a six-axis robot (www.bioassemblybot.com)
to construct living human tissue. BioAssemblyBot® is a disruptive technology that allows researchers to complete their experiments
faster, pharmaceutical companies to take cost and time out of the drug development process and a new approach to solve for diseased or
failing organs.

 

In
addition to selling the innovation to customers around the world, Advanced Solutions Life Sciences is using the BioAssemblyBot® technology
platform in its own labs to help advance the science including developments to support the goal of 3D printing human organs.

 

    	 

     

    

 

		 

                                                                                                                 2019 Frost & Sullivan Best

                                                                                                                 Practices Award Winner

 

BOSTON,
MA. & LOUISVILLE, KV. - 10 December, 2019 - Based on its recent analysis of global manufacturing for pharmaceuticals,
biotechnology, and cell & gene therapies, Frost & Sullivan recognizes Louisville-based Advanced Solutions life Sciences, LLC
(ASLS) with the 2019 Bioprinting Value Leadership Award. ASLS has demonstrated leadership in the category by introducing innovative,
best-in-class biofabrication hardware, software, and consulting services. Its flagship product is the BioAssemblyBot®, the world’s
only 3D bioprinter that gives users the flexibility, speed, and precision of a six-axis robotic arm to translate regenerative medicine
therapies from benchtop-to-bedside.

 

“ASLS
is an organization grounded in customer satisfaction & continuous improvement, delivering true value through their market-leading
30 bioprinters. It has developed an extensive ecosystem comprising of biofabrication, vascularization and machine learning software to
support adjacent applications in research laboratories to biopharmaceutical factories,’’ said Aarti Chitale, Senior Research
Analyst, Life Sciences, Frost & Sullivan. “ASLS is drastically simplifying the tissue engineering workflow, while expanding
experimental throughput by 20x in most cases”

 

While
30 bioprinting has become an essential tool for drug developers, procurement of bioprinting systems and hardware requires significant
capital expenditures and highly trained resources to operate these instruments, which imposes significant cost challenges tied to training
and procurement, especially for small and mid-segment players. Frost & Sullivan has identified Advanced Solutions Life Sciences as
a leading developer of unique, easy-to-use, and cost-effective solutions to support advancement of life-saving drugs via 3D bioprinting,
especially focused on the tissue engineering segment.

 

ASLS
demonstrates an unparalleled focus supporting curative therapy research, with its one-of-a kind BioAssemblyrM and AngiomicsTM technology
platforms. Its technology stands out from the competition by using biomimetic robotics and natural circulatory pathways to create functional
vasculatures for engineered tissues and organs. The company is strongly positioned across the United States, securing research and development
grants from NIH and ARMI to create specialized manufacturing workflows for clinical and non-clinical commercial activities. Its cost-effective
products ensure its strong market positioning as well as a growing customer base.

 

Frost
& Sullivan strongly believes that ASLS’s products have the potential to encourage cutting edge scientific discoveries and pave
the way towards developing advanced medical technologies for the overall betterment of humanity.

 

    	 

     

    

 

Table
of Contents

 

	1.	Confidentiality	5
	2.	Capabilities	5
	 	2.1	Advanced
    Solutions Life Sciences (ASLS)	5
	 	2.2	How
    the BioAssemblyBot®Technology Platform Works	6
	3.	TSIM® & BioAppsTM Software	7
	4.	BioAssemblyBot® Series 400	9
	 	4.1	Specifications	11
	5.	Platform-as-a-Service Configuration & Monthly Fee	12
	6.	Platform-as-a-Service Benefits	13
	Platform-as-a-Service offers the following customer benefits  	13
	7.	Terms and Conditions	14
	 	7.1	Intellectual
    Property	14

 

    	 

     

    

 

1.
Confidentiality

 

	This
                                            document contains confidential, proprietary information belonging to Advanced Solutions,
                                            Inc. and its subsidiaries including Advanced Solutions Life Sciences, LLC. Information contained
                                            in this report may not be released to or shared with any individual that is not affiliated
                                            with Biolife4D.

    

 

2.
Capabilities

 

2.1
Advanced Solutions Life Sciences (ASLS)

 

Advanced
Solutions Life Sciences (ASLS) is dedicated to the discovery, design, and development of integrated software, hardware, and biological
solutions for the biomedical and biotechnology fields of science and industry. ASLS offers a full service business model including its
patented BioAssemblyBot® 3D Biofabrication Technology Platforms, TSIM® Software, patent pending VIPMTM, Professional Services
and Supplies.

 

ASLS
is a subsidiary of 33-year old Advanced Solutions, Inc. (ASI) and is headquartered within a 15,000 square foot facility in Louisville,
Kentucky. In addition to it serving as the central office, the ASI facility houses the primary engineering teams comprised of systems
engineers, software engineers, mechanical engineers, simulation engineers, electrical engineers, and bioengineers. Projects are assigned
a specific team of engineers based on the expertise needed from this large collection of over 50 engineers and technical professionals.

 

 

 

ASLS
has a fully equipped engineering and manufacturing laboratory, a software design facility and biological research laboratories. In addition
to advanced manufacturing tools (including a variety of thermoplastic 3D printers), the entire company is connected on a Skype for Business
collaboration backbone (Instant Message, VOiP, Video Chat, Screen sharing). To supplement the effectiveness of this collaboration platform,
SMART Board Interactive Touch screens are used for brainstorming, design sessions, and other scenarios where thought capture is accomplished
digitally.

 

The
company has developed expertise in robust/scalable cloud infrastructures (ex: Amazon’s AWS) that allows for an agile approach to
software development. The TSIM® software and BAB printer was designed, prototyped, and assembled in this facility. There is also
a fully equipped 3,400 sq ft tissue culture (TC) wet lab and office in Manchester, New Hampshire for use in TSIM®/BAB testing and
application development, including microfluidics capabilities. The lab is organized such that the BAB can be located immediately adjacent
to the cabinet and incubator, providing seamless movement of cultures and constructs between these sterile environments.

 

    	Page 5

     

    

 

2.2
How the BioAssemblyBot® Technology Platform Works

 

It
starts with an idea! TSIM® Software enables you to turn the idea into a 3D digital prototype model. Enhance the tissue construct
idea through import of patient specific medical images and “what-if” the idea through TSIM®’s scenario manager
and flexible tissue materials library. Once a 3D model is built, the user sends the design to BioAssemblyBot® where a completely
automated workflow of material and 3D biofabrication takes place.

 

BioAssemblyBot®can
operate as a standalone workstation or integrate into other biofabrication steps including BioStorageBotTM.

 

 

BioAssemblyBot®builds
3D Tissue Structures and through the versatility of the robot arm and its end effector tools, sub-assembly structures can be 3D printed,
assembled, and incubated for a precise time and quality controlled workflow.

 

Fail
Fast with a scenario and leverage lessons learned to enhance and improve the tissue construct idea. The BioAssemblyBot® Technology
Platform brings some of the world’s most advanced biofabrication technology into a set of easy to use tools and an integrated agile
biofabrication work cell. Time is our most precious commodity. BioAssemblyBot®allows the user to spend their time advancing ideas,
advancing the science and bringing forward tissue applications quickly and efficiently.

 

    	Page 6

     

    

 

3.
TSIM® & BioAppsTM Software

 

Designing
and 3D printing tissue structures requires a software tool that enables easy and precise workflow. The Information Modeling capability
of TSIM® allows you to enhance the precision and functional specifications of any tissue structure design.

 

 

Digital
prototyping through TSIM® enables:

 

	 	● 	Design,
    visualize, and analyze precise and reproducible 3D computer models of structures
	 	● 	Image
    import and manipulation from patient specific image sets as a guide for structure design
	 	● 	Material
    inventory management to define, create, update, and administer data attributes and material assignments to objects within 30 models
	 	● 	Easily
    crop and adjust medical image density to isolate patient specific tissue structures
	 	● 	Intuitive
    user workflows to build simple to complex tissue geometry

 

 

    	Page7

     

    

 

Automate
& execute biofabrication protocols on BioAssemblyBot with our intuitive drag and drop workflow builder called BioAppsT”‘.
Users quickly stitch together experiments from simple to complex, taking full control of the biofabrication automation equipment available.

 

 

New
BioAppTM Worlifl.ow and Tissue Recipe Creation Tool in TSIM®

 

    	Page 8

     

    

 

4.
BioAssemblyBot® Series 400

 

The
patented and cGMP BioAssemblyBot® 6-axis robot gives you the freedom to biofabricate advanced 3D tissue structures and constructs
with several 3D printing and biofabrication capabilities including:

 

	 	●	Additive
    3D Printing
	 	●	Contour
    30 Printing
	 	●	Pick
    & Place control
	 	●	Assembly
	 	●	On-the-fly
    Interchangeable Tools
	 	●	Ease
    of Use with off the shelf Nordson® disposable syringes and a wide array of luer lock needle sizes
	 	●	Intuitive
    Touch Screen Interface
	 	●	Precision
    Temperature Control

 

	 	● 	Tool
    Storage Rack
	 	● 	While
    Connected to the Robot Arm
	 	● 	Print
    Stage

 

BioAssemblyBot®
maintains temperature control from -4 Celsius to 150 Celsius and can be adjusted during specific points in the 3D printing workflow through
the TSIM® Software.

 

 

    	Page 9

     

    

 

The
BioAssemblyBot® is the next stage of evolution in 3D bioprinting technology and is ideally suited for the precision required to assemble:

 

	 	●	Cell
    Systems and 3D Assays
	 	●	Experimental
    tissue models and microenvironments
	 	●	Organ
    models
	 	●	Microfluidic
    platforms
	 	●	Implant
    systems

 

 

Interchangeable
Tools Enable An Automated Robotic Workflow for 3D Bioprinting Projects

 

    	Page10

     

    

 

4.1
Specifications

 

	Connections	 	Power
    Supply Input
	 	 	RJ45
    CAT-5
	 	 	USB
    input (x2)
	 	 	 Pneumatic Air Fitting
	Air
    Requirements	 	140L/flow/min
    at 100 PSI
	Power
    Requirements	 	NEMA
    6-20R plug on a 208-220 reciprocal rated 20 Amps
	Weight	 	272
    kg
	Dimensions	 	93.5cm
    (w) x 75.0cm (d) x 134.3cm (h)
	Tool
    Storage	 	Up
    to 8 BioAssemblyBot® tools
	Build
Volume	 	30.48cm
    (I) x 25.4cm (w) x 17.78cm (h)
	HEPA
    Filtration	 	HEPA
    filters capture 99.97% of particles down to 0.3μ
	Integrated
    Temperature Control	 	Print
    Stage: 10-60°C
	 	 	Hot
    tool: Ambient-150°C (for thermoplastic bioinks)
	 	 	Cooling
    tool: -4°C-Ambient

 

    	Page 11

     

    

 

5.
Platform-as-a-Service Configuration & Monthly Fee

 

The
following system is configured based on Biolife4D’s requested tool package:

 

		●	BioAssemblyBot®400
    Series

 

	 	○	6-axis
    robot [ANSI/RIA RlS.06-1999/CE/JIS B 8433/UL1740]
	 	○	BioAssemblyBot®
    Controller
	 	○	Workstation
    access from three sides with door safety switches,
	 	○	300mm
    (11.8) width x 250mm (9.8) depth print stage
	 	○	(8)
    Syringe tool staging rack
	 	○	Tip
    detection station
	 	○	Fixed
    mount HD 1080p (up to1600 x 1200 pixels) video camera with print recording capability
	 	○	(4)
    LED workstation lights
	 	○	586.1kPa
    (85 psi) integrated pneumatic dispensing system
	 	○	Integrated
    HMI video display and connecting arm that is external to the unit and can be placed outside of a biosafety cabinet with a USB cable
    and a monitor cable that can run to the outside of the cabinet. Customer will be responsible for mounting HMI display outside of
    the biosafety cabinet.
	 	○	208-220
    20 Amp with a NEMA 6-20R power connector
	 	○	RJ45
    CAT-5 connector
	 	○	(2)
    USB inputs
	 	○	6.35mm
    (1/4) Pneumatic air connection

 

	 	●	BioAssemblyBot®
    HEPA Filtration System: Round lnline Exhaust Fan, 4” Duct (167 CFM). HEPA filters capture 99.97% of particles down to 0.3 microns
	 	●	BioAssemblyBot®
    Advanced Integrated Temperature Controlled Print Stage
	 	●	(Qty
    2) BioAssemblyToolTM 30 Syringe I Cold Pneumatic Dispense
	 	●	(Qty
    1) BioAssemblyTool71’’ 30 Syringe I 3/5/l0ml Mechanical Dispense
	 	●	(Qty
    1) BioAssemblyBot UV ring-light tool calibration system
	 	●	(Qty
    1) BioAssemblyToolTM 3D Syringe I 365nm UV Ringlight Pneumatic Dispense
	 	●	(Qty
    1) BioAssemblyToolTM 3D Dual Syringe I Mix Pneumatic Dispense
	 	●	(Qty
    1) Dual Dispense Tool adapter that supports coaxial dispense tips (Note: the BioAssemblyBot® Dual Dispense Tool is required
    for this adapter to work properly)
	 	●	(Qty
    2) BioAssemblyToolTM 3D Dual Syringe Pneumatic Dispense
	 	●	(Qty
    1) BioAssemblyTool1’“‘ 3D Syringe I 30ml Pneumatic Dispense
	 	●	(Qty
    1) BioAssemblyToolTM 3D Syringe I 10ml Pneumatic Dispense
	 	●	BioAssemblyToolTM
    Laser distance measuring and calibration
	 	●	BioAssemblvBot®
    table
	 	●	TSIM® Software
    Desktop Subscription Single-User
	 	●	BioAppsTM
    Software Desktop Subscription Single-User
	 	●	BioAssemblyBot®
    Advanced Onsite Services

 

	 	○ 	A
    certified BioAssemblyBot® engineer provides onsite setup, configuration and training for up to 10 customer employees for the
    initial workstation install. Training includes hands on building of TSIM® models and BioAppsTM workflows.

 

    	Page 12

     

    

 

	 	○ 	Annual
    PaaS onsite machine configuration, testing and certified factory calibration.
	 	○ 	Includes
    all travel expenses

 

	 	● 	BioAssemblyBot®
    400 PaaS Platinum Support and No Hassel Equipment Warranty

 

	 	○ 	Always
    stay up to date with access to the available software upgrades and controls improvement.
	 	○ 	Access
    to ASLS Biology, Engineering and Technical Support via email, IM and platinum phone support.
	 	○	Targeted
    up to 2 business hour response time
	 	○ 	Exclusive
    access to ASLS collaboration 3D print strategies portal. This portal contains videos and ideas on the latest protocols for 3D printing
    strategies using the BioAssemblyBot® and TSIM® Software
	 	○ 	Up
    to 20 hours per customer for consulting services. Hours can be used for training, design services, etc.
	 	○ 	Online
    case tracking tool through the Customer Portal

 

	 	● 	100
    Service Credit hours that will be used for service/engineering/software programming. Advanced Solutions Life Sciences will provide
    a written scope as Customer need arises and Customer written approval will be required before hours are used. A leader per project
    will also be assigned to the customer.
	 	● 	Shipping
    for both delivery to customer site and return to Advanced Solutions at the end of the contract

 

Access
to this entire package is available for a monthly service fee offered below with a minimum of 3-year commitment. After the 3-year commitment,
the equipment can be returned to Advanced Solutions or continued to be used on a month-to-month basis.

 

	PaaS Monthly Service Fee	 	$	9,000	 

 

6.
Platform-as-a-Service Benefits

 

Platform-as-a-Service
offers the following customer benefits:

 

	 	●	Low
    upfront expense
	 	●	Smoother
    cash flow
	 	●	Operational
    expense as opposed to capital expenditure
	 	●	No
    hidden fees - the PaaS monthly investment is all inclusive of hardware, support and maintenance
	 	●	Easy
    to scale
	 	●	Stay
    current with the latest technology updates
	 	●	Easy
    to add new BioAssemblyToolsTM - prorated to the existing contract
	 	●	No
    Hassel Maintenance or Repair - You’re not responsible for maintenance or repairs
	 	●	Obsolescence
    isn’t a problem - when new technology is available the contract can be modified to give you a choice for upgrade and cross
    grade options.

 

    	Page 13

     

    

 

7.
Terms and Conditions

 

The
additional terms and conditions specified on the attached Platform as a Service Contract and Conditions shall apply with full force and
effect to this Agreement and are specifically incorporated by reference as if set forth here in full.

 

7.1
Intellectual Property

 

All
ASLS patented or patentable inventions, and know-how
covering the technology subject to this tender, including but not limited to U.S. Patents No. 9,910,935; 10,392,595; 15/726,617; 15/793,872;
16/076,051; 16/135,299; 16/512,954; 16/152,680; 16/264,833; 16/502,795; 16/811,808; 16/832,989; 16/831,243; 16/843,951; 16/891,153; 16/906,391;
16/906,156; 16/993,815; 17/030,796; 17/061,625; 62/914,053; 62/969,320 and 63/051,957 are and shall remain the sole property of ASLS.

 

    	Page 14

     

    

 

 BioAssemblyBot®

Platform
as a Service

 

	1.
                                                                                          Agreement.

     

    These
    Terms and Conditions between Advanced Solutions Life Sciences, LLC (“ASLS”) and Biolife4D [NEED FULL NAME]., (“Biolife4D”)
    for the use of the BioAssemblyBot® Platform as a Service represent the entire agreement and understanding between the parties
    {the ‘‘Agreement”). In the event of a conflict between the terms of this Agreement and any quote, purchase order,
    proposal, or other document submitted by Biolife4D prior to or after entering into this Agreement, this Agreement shall control.
    As applicable, ASLS and Biolife4D may each be referred to herein individually as a ‘‘party” and collectively as
    the “parties.”

     

    2.
    Platform as a Service.

     

    ASLS
    shall furnish Biolife4D with a BioAssemblyBot® 400 (‘‘BAB”) and accompanying TSIM® and BioAppsTM
    software (“Software”) {collectively, the “Equipment’1 along with certain tools, devices and related services
    comprising the BAB Platform as a Service {collectively the ‘‘Service”) pursuant to the terms of this Agreement.
    Provided Biolife4D complies with all the provisions of this Agreement, ASLS shall (i) deliver and install the BAB at a location
    designated by Biolife4D at no cost to Biolife4D; (ii) provide training on the use of the BAB at no cost to Biolife4D; and (iii)
    provide maintenance and repairs of the BAB at no cost to Biolife4D pursuant to ASLS Platinum Support Package as provided for in
    Section 10 below. Biolife4D may add ASLS’ tools during the Term and the Agreement will be amended to add a prorated charge for
    the tool for the remainder of the Term.

     

    3.
    Payments.

     

    (a)
    Biolife4D agrees to remit to ASLS a monthly fee of “Monthly Fee”) for use of the Services for a term of three
    (3) years from the Commencement Date (the “Term”). The Commencement Date shall be the date the BAB is delivered to the
    location specified by Biolife4D. Biolife4D will submit the first Monthly Fee payment prior to shipment of the BAB. Thereafter, Biolife4D
    shall submit the Monthly Fee every thirty days. after the Commencement Date for the remainder of the Term. At the end of the Term,
    Biolife4D may (i) return the Equipment to ASLS, (ii) purchase the Equipment pursuant to Section 3(b); or (iii) continue to utilize
    the Service and Equipment on a month to month basis at ASLS’ then current monthly rate until either party provides thirty (30)
    days written notice of its intent to terminate the Agreement.
	 	(b)
Upon the expiration of the Term and provided payments are current and Biolife4D is in good standing with ASLS, Biolife4D shall have the
option to purchase the Equipment for $29,872.00. The Equipment will be sold “as is” and any additional warranty or platinum
support will have to be purchased separately.

     

    (c)
    Biolife4D shall pay interest at the rate of 1-1/2% per month or the highest legal interest rate, whichever is lower, on all overdue
    amounts. Biolife4D shall provide ASLS with appropriate documentation if any exemption from sales or use taxes is claimed.

     

    (d)
    If Biolife4D fails to pay the Monthly Fee or other amount herein provided within five (5) calendar days after the same fs due and
    payable, or if Biolife4D fails to observe, keep or perform any other provision of this Agreement required to be observed,
    kept or performed, ASLS shall have the right to exercise any one or more of the following remedies provided ASLS has provided written
    notice of such breach or default and such breach or default remains uncured for ten (10) calendar days after Biolife4D receives notice:
    (i) to declare the entire amount of unpaid Monthly Fees for the remainder of the Term immediately due and payable without notice
    or demand to Biolife4D; (ii) to file a claim for and recover all payments, then accrued or thereafter accruing; (iii) to deactivate
    the Equipment so that it is no longer operational; (iv) take possession of the Equipment, without demand or notice, wherever same
    may be located, without any court order or other process of law; (v) to terminate this Agreement; and (vi) to pursue any other remedy
    at law or in equity.

     

    (e)
    Biolife4D hereby waives any and all damages occasioned by such taking of possession. Notwithstanding any repossession or any other
    action which ASLS may take, Biolife4D shall be and remain liable for the full performance of all obligations on the part of the BioLife4D
    to be performed under this Agreement All of ASLS’s remedies are cumulative and may be exercised concurrently or separately.

     

    (f)
    As additional security for the payment and performance of all obligations under this Agreement, Biolife4D hereby pledges, assigns
    and grants to ASLS a continuing security interest in all of its assets. Biolife4D will execute a UCC-1 financing statement in connection
    with such security interest.

 

    	Page 15

     

    

 

	4.
                                            Security Deposit.

     

    Biolife4D
    shall pay a security deposit in the following amount prior to taking possession of the Equipment: $18,000.00 dollars. The security
    deposit will be refunded to Biolife4D within 60 days following Biolife4D’s return of the Equipment and verification that the
    Equipment is in good working order. Prov1ded that, ASLS may use the funds from the security deposit to pay for any damages to the Equipment,
    any amounts past due from Bfolife4D, any cost incurred by ASLS in obtaining the Equipment from Biolife4D and any cost incurred by
    ASLS as a result of Biolife4D’s breach of this Agreement. The use of funds from the Security Deposit does not limit
    any other remedies that ASLS may take at law or in equity,

     

    5.
    Insurance.

     

    Biolife4D
    shall procure and continuously maintain and pay for all risk insurance against loss of and damage to the Equipment for not less Three
    Hundred and Fifty Thousand Dollars ($350,000), naming ASLS as loss payee, and combined public liability and property damage insurance
    with limits not less than Two Million Dollars ($2,000,000), naming Lessor as additionally named insured and a loss payee. The insurance
    shall be in such form and with such company or companies as shall be reasonably acceptable to ASLS, shall provide at least thirty
    (30) days advance written notice to ASLS of any cancellation, change or modification, and shall provide primary coverage for the
    protection of Biolife4D and ASLS without regard to any other coverage carried by Biolife4D or ASLS protecting against similar risks.
    Biolife4D shall provide ASLS with an original policy or certificate evidencing such insurance prior to shipment of the Equipment.

     

    6.
    Ownership of Equipment

     

    The
    BioAssemblyBot® 400 and accompanying Software along with any tools and devices comprising the BAB Platform as a Service provided
    to Biolife4D are exclusively owned by ASLS. The BAB includes proprietary software and documentation owned by ASLS, which is hereby
    licensed to Biol-ife4D under a non-exclusive, non transferable, cancellable license solely for Biolife4D’s own internal use
    in connection with the use of the BAB and in accordance with the user documentation provided by ASLS. Biolife4D agrees that it shall
    only use the BAB and Software for research purposes. Biolife4D shall not (a) modify copy, enhance make derivative works of the
    Software or the BAB, (b) disassemble, decompile, reverse engineer the Software or the BAB or otherwise derive human readable code
    from the Software, (c) resell the BAB or Software to any third party, or (d) license, sublicense, Agreement, rent, assign, transfer,
    or otherwise distribute the Software or the BAB. Biolife4D may not copy or modify in whole or in part the Software nor make it available
    in any form to any third party. ASLS shall have the right to terminate the license to the Software if Biolife4D fails to comply with
    any term or condition of this Agreement.
	 	7.
                                            Risk of Loss.

     

    Biolife4D
    hereby assumes and shall bear the entire risk of loss and damage to the Equipment from any and every cause whatsoever while it is
    in its possession. No loss or damage to the Equipment or any part thereof shall impair any obligation of Biolife4D under this Agreement,
    which shall continue in full force and effect through the term of the Agreement. In the event of loss or damage of any kind whatever
    to the Equipment, Biolife4D shall, pay to ASLS the replacement cost of the Equipment.

     

    8.
    Return of Equipment.

     

    Within
    10 days upon the expiration or earlier termination of this Agreement (the “Equipment Return Period”), Biolife4D shall
    return the Equipment to ASLS in good repair, condition and working order, ordinary wear and tear resulting from proper use thereof
    excepted, by delivering the Equipment at BioLife4D’s cost and expense to such place as ASLS shall specify and pursuant to ASLS’s
    packing instructions. In the event Biolife4D fails to deliver the Equipment Biollfe4D shall incur a late fee charge in the amount
    of $100.00 per day that Biolife4D is late delivering the Equipment to ASLS after the Equipment Return Period. Notwithstanding the
    foregoing, ASLS may elect to retrieve the Equipment and Biolife4D shall be responsible for reimbursing ASLS for all cost associated
    with retrieving the Equipment, including cost for personnel retrieving the Equipment, travel time and expenses, shipping cost
    and all other reasonable expenses. Biolife4D agrees to cooperate with ASLS should it elect to retrieve the Equipment.

     

    9.
    Improvements/Developments.

     

    Title
    to all inventions and discoveries made solely by Biolife4D resulting from its operation of the BAB and the Software shall be owned
    by Biolife4D (“New Printing Technology”). Title to any modification or improvement to the BAB, such as a new tool shall
    be owned by the Biolife4D (“Improvement”). Notwithstanding Biolife4D’s ownership of any Improvement or New Printing
    Technology, in no way shall such ownership convey or confer ownership of ASLS’ intellectual property rights in and to the BAB
    or the Software to the Biolife4D. Blolife4D may commercialize and license any New Printing Technology or Improvement without any
    agreement or compensation to ASLS. However, if a BAB and the Software are necessary to utilize the New Printing Technology or Improvement,
    the BAB and the Software may only be purchased from ASLS. Notwithstanding any Biolife4D Improvements or New Printing Technologies
    and any ownership thereto, Biolife4D expressly agrees that ASLS shall in no way be prohibited from developing, using, selling or otherwise exploiting any modification or improvement to the BAB that
it originates similar to Biolife4D’s Improvement or New Printing Technologies and with no compensation or remuneration of any kind
to Biolife4D provided it does not violate any of Biolife4D’s IP ownership rights.

    

 

    	Page 16

     

    

 

	10.
Platinum Support.

     

    During
    the Term of this Agreement ASLS shall provide Biolife4D with platinum Support at no cost as follows:

     

    (a)
    Repair or replace all defects in the BAB or Software, including no cost for travel.

    (b)
    Access to ASLS Biology, Engineering and Technical Support via email.

    (c)
    Targeted 4 business hour email response time

    (d)Access
    to ASLS biology, engineering and technical Support via telephone

    (e)
    Access to remote screen sharing and remote diagnostics.

    (f)
    Exclusive access to ASLS collaboration 3D print strategies portal. This portal contains videos and ideas on the latest protocols
    for 3D printing strategies using the BAB and accompanying Software.

    (g)
    Up to 20 hours of Software Product Design Assistance and 3D printing biology collaboration per year.

    (h)
    Online case tracking tool (Customer Portal).

    (i)
    Annual( onsite maintenance and factory calibration performed by a certified ASLS technician. Includes all travel expenses

     

    ASLS
    reserves the right to upgrade the Equipment and replace any old Equipment as it deems necessary at no cost to Biolife4D. Biolife4D
    agrees to provide ASLS with access to the Equipment for maintenance, upgrades and replacement upon reasonable notice from ASLS.

     

    Platinum
    Support will not apply to defects resulting from misuse, neglig.ence or accident, including, without limitation: operation outside
    of the environmental specifications for the BAB; use of unauthorized supplies; performance of improper or inadequate maintenance by
    Biolife4D or any third party; installation of software not supplied by ASLS; any attempt by Biolife4D or its agents or employees to
    gain access to those areas of the BAB accessible only to authorized service personnel; any attempt by the Biolife4D or its agents or
    employees to service those aspects of the BAB that may only be serviced by authorized ASLS personnel;,rmproper use or connection to
                                            incompatible equipment; modifications to the BAB not authorized by ASLS; and external causes
                                            such as, but not limited to, power failure and force majeure. Any repairs or services that
                                            are performed by ASLS not covered by Platinum Support shall be billed to Biolife4D at ASLS’s
                                            then current hourly rate.
	 	

    11.
    Liability

     

    IN
    NO EVENT SHALL ASLS BE LIABLE TO BIOLIFE4D OR ANY THIRD PARTY FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE
    OR OTHER INDIRECT DAMAGES, OR FOR LOSS OF PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES, ARISING OUT OF THE OPERATION OF THE BAB,
    THE MANUFACTURE, AGREEMENT OR SUPPLY OF THE_ BAB OR ITS USE OR DISPOSITION, EVEN IF ASLS HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
    DAMAGES OR LOSSES.

     

    12.
    Indemnification.

     

    Biolife4D
    agrees to indemnify, defend and hold ASLS and its parent, subsidiary, or affiliated companies (“Affiliates”), shareholders,
    directors, officers, employees, agents and assignees harmless from and against any expenses incurred by or claims made against ASLS
    arising out of any actions of Biolife4D including but not limited to the use of the BAB, or the improper modification to the BAB.
    actual or alleged breach or violation of any contract, law, rule, regulation, or by-law; breach of any provision of these terms;
    and acts, errors or omissions of Biolife4D or any of its agents, servants, employees, contractors, partners, shareholders, affiliates
    or representatives. For purposes of this indemnification, the term “expenses or claims’’ shall mean and include
    (i) all losses, obligations, expenses (as incurred), actual and consequential damages, taxes and costs reasonably incurred in preparing
    for, defending or settling any demand, investigation, suit, action, claim, inquiry or proceeding, whether or not a formal Inquiry,
    proceeding or investigation had been commenced; and (i reasonable accountants’, legal and expert witness fees. Biolife4D shall
    give ASLS immediate written notice of any demand, investigation, inquiry, action, suit, proceeding or claim. ASLS at its sole option
    shall have the right to defend at BioLife4D’s expense any such liability or daims in which either ASLS or Biolife4D or both
    are named as defendants, or reasonably are expected to be named, and ASLS shall not be obligated to mitigate losses. ASLS’s
    conduct of the defense shall not diminish Biolife4D’s obligation to indemnify ASLS hereunder. This indemnity shall continue
    in full force and effect subsequent to and notwithstanding any termination of this Agreement or any Quote.

     

    	Page17

     

    

 

	13.
                                            Choice of Law

     

    Any
    disputes arising in connection with this Agreement will be governed exclusively by and be construed exclusively in accordance
    with the internal laws of the Commonwealth of Kentucky, without reference to its conflicts of laws principles. Biolife4D hereby consents
    and submits to the jurisdiction of the federal and state courts located in Jefferson County, Kentucky and agrees it will not institute
    an action in any other jurisdiction. The prevailing party in any litigation shall be entitled to be reimbursed for its legal fees
    and cost from the other party.

     

    14.
    Notices.

     

    All
    notices given in connection with this Agreement shall be in writing and transmitted to the addresses provided by the parties by (i)
    recognized overnight commercial courier with proof of receipt; (ii) certified mail, return receipt requested, postage prepaid; or
    (iii) email to the email address provided, and will be deemed received upon date sent.

     

    15.
    Confidential Information.

     

    Both
    parties agree to hold in strict confidence the terms of this Agreement and all information provided by a party (the “disclosing
    party”) to the other party (the “receiving party”) in connection with the performance of their respective obligations
    under this Agreement that is either marked or identified as the confidential information of the disclosing party, or which, by its
    nature, the receiving party would reasonably deem to be confidential, including the Software, any Improvements, financial information
    and pricing information (“Confidential Information”), except to the extent that disclosure is required by applicable
    law. Either party may disclose the terms of this Agreement and/or Confidential Information of a disclosing party to its employees,
    professional advisors, agents or independent contractors that are providing services for such party, require the knowledge of such
    terms or Confidential Information, and are subject to applicable confidentiality obligations or non-disclosure agreements. The receiving
    party agrees not to use any Confidential Information of the disclosing party for any purpose except in the performance of its obligations
    hereunder or as otherwise permitted

    hereunder.

     

    16.
    Miscellaneous.

     

    (a)
    Biolife4D shall comply with all applicable laws governing the use of the BAB and the enforceability and performance of this Agreement.

     
	 	(b)
                                            Biolife4D may not assign any interest in this Agreement without the prior written consent
                                            of ASLS. Subject to the foregoing, the rights and obligations herein will be binding upon
                                            the successors and permitted assigns of both ASLS and Biolife4D. ASLS’s failure to
                                            exercise any of its rights will not constitute or be deemed a waiver or forfeiture of any
                                            rights hereunder. If any of these provisions are held to be invalid, illegal or unenforceable,
                                            the validity, legality and enforceability of the remaining provisions will not in any way
                                            be affected or impaired.

     

    (c)
    No provision of this Agreement shall be waived, amended, modified, superseded, canceled, terminated, renewed or extended except in
    a written document signed by an authorized representative from both parties hereto. The headings of the several sections are inserted
    for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.

    	Page 18

     

    

 

This
Agreement is accepted and agreed to by the authorized representative of each party.

 

	BIOLIFE4D
  [NEED FULL NAME]	ADVANCED
  SOLUTIONS LIFE SCIENCES, LLC

 

	By:	/s/
    Steven Morris		By:	/s/
    Michael Golway
	Name:	Steven
    Morris	 	Name:	Michael
    Golway
	Title:	CEO	 	Title:	President
    & CEO
	Date:	12-20-21	 	Date:	12/21/2021

 

    	Page 19Exhibit
10.33

 

INDEPENDENT
CONTRACTOR AGREEMENT

 

This
Independent Contractor Agreement (the “Agreement”) is made and entered into as of the date set forth on the initial Statement
of Work, as may be amended from time to time (the “Initial SOW”), attached here to as Exhibit A (the “Effective
Date”) between BioLife4D Corporation (“Company”), the person whose name and address are set forth on the Initial SOW
(“Consultant”).

 

In
consideration of the covenants and conditions hereinafter set forth, Company and Consultant agree as follows:

 

1. SERVICES.
Consultant shall perform the services (the “Services”) set forth in the Initial SOW and each Statement of Work attached here
to as Exhibit A (each a “Statement of Work” or “SOW”) which is an integral part of the Agreement. A Statement
of Work may be amended or modified from time to time, provided that each party acknowledges such amendment or modification in writing.

 

2. COMPENSATION.
The Compensation for Services (the “Compensation”) performed under this Agreement shall be as set forth in the corresponding
Statement of Work.

 

3. TERM.
The term of this Agreement (the “Term”) shall commence upon the Effective Date and continue for as long as Consultant is
obligated to perform Services under any Statement of Work; provided, however, that either party may terminate this Agreement, or any
SOW attached hereto, at any time with prior written notice (in the number of calendar days set forth in the Initial SOW) delivered to
the email address(es) as set forth in the Initial SOW, without cause and without any further obligation to the other party except for
any payments due as of the date of such termination. In such a case the payments shall be paid on daily pro-rated basis. Termination
of this Agreement, or any SOW attached hereto, shall not affect the representations and warranties and covenants under this Agreement,
which shall survive any termination.

 

4. WORK
SCHEDULE. The Work Schedule (the “Work Schedule”) of the Consultant under this Agreement shall be as set forth in the
Statement of Work.

 

5. CONFIDENTIALITY

 

	 	(a)	As
    used herein, the terms (i) “Confidential Information” means any and all confidential and/or proprietary knowledge, data
    or information of the Company, its affiliates, parents and subsidiaries, whether having existed, now existing, or to be developed
    in the future and includes (A) trade secrets, inventions, mask works, ideas, processes, formulas, source and object codes, data,
    programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques and any other proprietary
    technology and all Proprietary Rights (as defined below) therein (hereinafter collectively referred to as “Inventions”);
    (B) information regarding research, development, new products, marketing and selling, business plans, budgets and unpublished financial
    statements, licenses, prices and costs, margins, discounts, credit terms, pricing and billing policies, quoting procedures, methods
    of obtaining business, forecasts, future plans and potential strategies, financial projections and business strategies, operational
    plans, financing and capital-raising plans, activities and agreements, internal services and operational manuals, methods of conducting
    Company business, suppliers and supplier information, and purchasing; (C) information regarding customers and potential customers
    of the Company, including customer lists, names, representatives, their needs or desires with respect to the types of products or
    services offered by the Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and
    services provided or sought to be provided to customers and potential customers of the Company and other non-public information relating
    to customers and potential customers; (D) information regarding any of the Company’s business partners and their services,
    including names; representatives, proposals, bids, contracts and their contents and parties, the type and quantity of products and
    services received by the Company, and other non-public information relating to business partners; (E) information regarding personnel,
    employee lists, compensation, and employee skills; and (F) any other non-public information which a competitor of the Company could
    use to the competitive disadvantage of the Company, but shall not include (Y) information that was already within the public domain
    at the time the information is acquired by Consultant, or (Z) information that subsequently becomes public through no act or omission
    of the Consultant, and (ii) “Proprietary Rights” shall mean all trade secrets, patents, copyrights, trademarks, mask
    works and other intellectual property rights throughout the world.

 

    	1

     

    

 

	 	(b)	Consultant
    recognizes and acknowledges that Company possesses certain Confidential Information that constitutes a valuable, special, and unique
    asset. Consultant agrees that all of the Confidential Information is and shall continue to be the exclusive property of Company,
    whether or not prepared in whole or in part by Consultant and whether or not disclosed to or entrusted to Consultant’s custody.
    Consultant agrees that Consultant shall not, at any time following the execution of this Agreement, use or disclose in any manner
    any Confidential Information of Company.
	 	 	 
	 	(c)	Consultant
    recognizes that the Company has received and, in the future, will receive from third parties their confidential or proprietary information
    subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain
    limited purposes. Consultant agrees that Consultant owes the Company and such third parties, during the term of this Agreement and
    thereafter, a duty to hold all such confidential or proprietary information in the strictest confidence and not to disclose it publicly
    nor to any person or entity or to use it except as necessary in carrying out the Services for the Company consistent with the Company’s
    agreement with such third party. All such third-party information will, as between the Company and Consultant, be deemed to be the
    Company’s Confidential Information for purposes of this Agreement.
	 	 	 
	 	(d)	During
    Consultant’s engagement by the Company, Consultant will not improperly use or disclose any confidential information or trade
    secrets, if any, of any person to whom Consultant have an obligation of confidentiality, and Consultant will not bring onto the premises
    of the Company any unpublished documents or any property belonging to any such person unless consented to in writing by such person.
	 	 	 
	 	(e)	Consultant
    agrees to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that may
    be required by the Company) of all Confidential Information developed by Consultant and all Inventions made by Consultant during
    the period of Consultant’s engagement at the Company, which records shall be available to and remain the sole property of the
    Company at all times.
	 	 	 
	 	(f)	Consultant
    agrees that no license is granted to Consultant in or to any potential patent, copyright, trademark, tradename or any other intellectual
    property or rights of Company included in the Confidential Information. Company is making no representation or warranty that the
    Confidential Information does not infringe on any patent, copyright, trademark, tradename or any other intellectual property right
    of third parties.
	 	 	 
	 	(g)	In
    the event Consultant is requested or required (whether by subpoena, oral deposition, interrogatories, request for production of documents,
    administrative order or otherwise) to disclose any Confidential Information or the fact that Confidential Information has been made
    available to Consultant, Consultant will provide Company with prompt notice of such request or requirement, so that Company may seek,
    at its expense, an appropriate protective order, or so that Company may waive compliance with the terms of this Agreement. In the
    absence of such protective order or waiver, Consultant may disclose only that portion of the Confidential Information as is legally
    required to be disclosed.

 

    	2

     

    

 

6. OWNERSHIP

 

	 	(a)	Subject
    to subsection (b) below, Consultant agrees that all work product of any kind developed or produced under this Agreement, in connection
    with the Services, including but not limited to the work product specified in Exhibit A, as well as all works of authorship
    and other copyrightable material, notes, records, drawings, technology, software, source code, designs, inventions, processes, improvements,
    developments, discoveries and trade secrets, whether or not patentable or registrable under patent, trademark, copyright or similar
    laws, conceived, discovered, developed or reduced to practice by Consultant, solely or in collaboration with others, during the term
    of this Agreement which relate in any manner to the business of Company that Consultant may be directed to undertake, investigate
    or experiment with, or which Consultant may become associated with in work, investigation or experimentation in Company’s line
    of business in performing the Services hereunder (collectively, “Work Product”) and all intellectual property and associated
    rights therein and thereto are the sole property of Company. Consultant further agrees to make full written disclosure to Company,
    to hold in trust for the sole benefit of Company, and to assign (or cause to be assigned), and does hereby assign fully, to Company
    all Work Product and any and all rights, title and interests in and to any and all copyrights, patents, mask work rights or other
    intellectual property rights relating thereto. Consultant hereby waives any and all rights of attribution, moral rights and similar
    rights wherever existing in and to any of the foregoing. Consultant agrees to keep and maintain adequate and current records (in
    the form of notes, sketches, drawings and in any other form that may be required by the Company) of all Confidential Information
    developed by Consultant and all Work Product made by Consultant during the period of Consultant’s engagement at the Company,
    which records shall be available to and remain the sole property of the Company at all times.
	 	 	 
	 	(b)	Consultant
    agrees that if in the course of performing the Services, Consultant incorporates into any Work Product developed hereunder any invention,
    improvement, development, concept, discovery or other proprietary information owned by Consultant or in which Consultant has an interest
    (each a “Prior Invention”), (i) Consultant shall inform Company, in writing before incorporating such invention, improvement,
    development, concept, discovery or other proprietary information into any Work Product; and (ii) Company is hereby granted and shall
    have a nonexclusive, royalty-free, perpetual, irrevocable, transferrable, sublicensable, worldwide license to use, perform, display,
    make, reproduce, make derivative works, import, sell, offer for sale, license, distribute, and otherwise dispose of such invention,
    improvement, development, concept, discovery or other proprietary information as part of or in connection with such Work Product,
    with the right to license such rights to others. To preclude any possible uncertainty, Consultant has set forth on Exhibit B
    attached hereto a complete list of all Prior Inventions. Consultant shall not incorporate any third-party product, software (including,
    without limitation, open source software and freeware) or work of authorship nor any invention, process, improvement, development,
    concept, discovery or trade secret or other confidential or proprietary information owned by any third party into any Work Product
    without Company’s prior written permission.
	 	 	 
	 	(c)	Consultant
    agrees to assist Company, or its designee, at Company’s expense, in every proper way to secure Company’s rights in the
    Work Product and any copyrights, patents, mask work rights or other intellectual property rights relating thereto in any and all
    countries, including the disclosure to Company of all pertinent information and data with respect thereto, the execution of all applications,
    specifications, oaths, assignments and all other instruments which Company shall deem necessary in order to apply for and obtain
    such rights and in order to assign and convey to Company, its successors, assigns and nominees the sole and exclusive right, title
    and interest in and to such Work Product, and any copyrights, patents, mask work rights or other intellectual property rights relating
    thereto. Consultant further agrees that Consultant’s obligation to execute or cause to be executed, when it is in Consultant’s
    power to do so, any such instrument or papers shall continue after the termination of this Agreement. Consultant agrees that if Company
    is unable because of Consultant’s unavailability, dissolution, mental or physical incapacity, or for any other reason, to secure
    Consultant’s signature to apply for or to pursue any application or registration for any United States or foreign patents,
    copyright or other formal intellectual property protection covering the Work Product assigned to Company above, then Consultant hereby
    irrevocably designates and appoints Company and its duly authorized officers and agents as Consultant’s agent and attorney-in-fact,
    to act for and in Consultant’s behalf and stead to execute and file any such applications and to do all other lawfully permitted
    acts to further the prosecution and issuance of patents, copyright registrations and other formal intellectual property protections
    thereon with the same legal force and effect as if executed by Consultant.
	 	 	 
	 	(d)	During
    the period of Consultant’s engagement and for six months after termination of Consultant’s engagement with the Company,
    Consultant will promptly disclose to the Company fully and in writing all Work Product or other inventions authored, conceived or
    reduced to practice by Consultant, either alone or jointly with others. In addition, Consultant will promptly disclose to the Company
    all patent applications filed by Consultant or on Consultant’s behalf within a year after termination of engagement. At the
    time of each such disclosure, Consultant will advise the Company in writing of any Work Product or other inventions that Consultant
    believes fully qualify for protection under any specifically applicable state law, regulation, rule, or public policy (“Specific
    Inventions Law”); and Consultant will at that time provide to the Company in writing all evidence necessary to substantiate
    that belief. The Company will keep in confidence and will not use for any purpose or disclose to third parties without Consultant’s
    consent any confidential information disclosed in writing to the Company pursuant to this Agreement relating to Inventions that qualify
    fully for protection under a Specific Inventions Law. Consultant will preserve the confidentiality of any Invention that does not
    fully qualify for protection under a Specific Inventions Law.

 

    	3

     

    

 

7. RETURN
OF MATERIALS. Consultant agrees that upon termination of this Agreement, Consultant will return to the Company (a) any and all drawings,
notes, memoranda, specifications, devices, formulas, and documents, together with all copies thereof, (b) any other material containing
or disclosing any Work Product or Confidential Information of the Company and (c) any other Company property. Consultant will not retain
any such materials.

 

8. WARRANTIES.
Consultant warrants that:

 

	 	(a)	Consultant’s
    agreement to perform the Services pursuant to this Agreement does not violate any agreement or obligation between Consultant and
    a third party;
	 	 	 
	 	(b)	the
    Services performed (and any work delivered in connection therewith, including any Work Product) as delivered to the Company will
    not infringe any copyright, patent, trade secret, or other proprietary right held by any third party; and
	 	 	 
	 	(c)	the
    Services provided by Consultant shall be performed in a professional manner, and shall be of a high grade, nature, and quality. The
    Services shall be performed in a timely manner and shall meet deadlines agreed between Consultant and the Company.

 

9. Restrictive
Covenants.

 

	 	(a)	Definition
    of Company. For purposes of this Section 9 only, the term “Company” shall be deemed to include the Company
    and all of its affiliates.
	 	 	 
	 	(b)	Consideration
    and Acknowledgement. Consultant acknowledges that: (i) the Company is and will be engaged in the business of the Company while
    Consultant is employed by the Company and thereafter; (ii) the Company is and will be actively engaged in the business of the Company
    throughout the world; (iii) Consultant is one of a limited number of persons who will be developing the business of the Company;
    (iv) Consultant has and will continue to occupy a position of trust and confidence with the Company while he, she or it provides
    services to the Company, and has and will continue to acquire an intimate knowledge of all the Company’s trade-secrets and
    other proprietary and confidential information concerning the business of the Company; (v) the agreements and covenants contained
    in this Section 9 are essential to protect the Company and its goodwill; (vi) the scope and duration of the restrictive covenants
    set forth in this Section 9 are reasonably designed to protect a protectable interest of the Company and are not excessive
    in light of the circumstances; and (vii) Consultant has a means to support themself and Consultant’s dependents other than
    by engaging in the business of the Company, or a business similar to the business of the Company, and the provisions of this Section
    9 will not impair such ability. Consultant further acknowledges that the Company is relying on the covenants and agreements set
    forth in this Section 9, and that the consideration to be received by Consultant pursuant to the terms of this Agreement is
    sufficient consideration to make the covenants and agreements set forth herein enforceable.

 

    	4

     

    

 

	 	(c)	Non-Solicitation
    and Non-Hire of Employees or Consultants. The Company’s employees, contractors, consultants, advisors and agents are essential
    to the Company’s operation, and the Company has an interest in maintaining a stable workforce. Consultant acknowledges that
    as a result of his, her or its relationship with the Company, Consultant will learn the identity of the Company’s employees,
    contractors, consultants, advisors and agents and other information about the terms of their employment or relationship with the
    Company, including the compensation and other amounts paid by the Company to its employees, contractors, consultants, advisors and
    agents. As a result, Consultant agrees that during the Term and for a period of 24 months following the termination of Consultant’s
    engagement with the Company for any reason, Consultant will not, separately or in association with others, directly or indirectly,
    whether as employee, owner, agent, independent contractor, advisor, joint venturer, consultant or in any other individual or representative
    capacity, (i) solicit the employment or retention of, or attempt to solicit the employment or retention of, for Consultant or any
    third party, any person who (x) is engaged by the Company as an employee, consultant, sales contractor or agent at the time of such
    solicitation (or attempted solicitation), (y) was so engaged by the Company within 12 months prior to such solicitation (or attempted
    solicitation) or (z) Consultant had work-related dealings with while employed with the Company, (ii) hire, engage or retain any such
    person, or (iii) induce, encourage or solicit or attempt to induce, encourage or solicit any employee, consultant, sales contractor
    or agent of the Company to discontinue employment with or services to the Company.
	 	 	 
	 	(d)	Non-Solicitation
    of Customers and Financial Contributors. Through the expenditure of significant time, effort and money, the Company has developed
    and maintained, and continues to develop and maintain, long-standing and near-permanent relationships with its customers and/or sources
    of financing. Consultant will have access to and contact with the Company’s customers, sources of financing and/or access to
    Confidential Information concerning those customers and/or sources of financing. Consultant may develop, on behalf of the Company,
    relationships with new customers and this relationship may constitute the Company’s only or primary contact with such customers.
    Consultant acknowledges and agrees that any relationships between Consultant and the Company’s customers and/or sources of
    financing were developed solely for the Company’s benefit. Consultant acknowledges and agrees that he, she or it would not
    have had access to the Company’s existing, new, and potential customers, sources of financing and/or Confidential Information
    concerning such customers and/or sources of financing but for their relationship with the Company. During the Term and for a period
    of 12 months following the termination of Consultant’s engagement with the Company for any reason, Consultant will not, separately
    or in association with others, directly or indirectly, whether as employee, owner, agent, independent contractor, joint venturer,
    consultant, advisor or in any other individual or representative capacity, (a) communicate with any Company Customer (as defined
    below) and/or source of financing for any business purpose, (b) solicit, induce or encourage or attempt to solicit, induce or encourage
    any Company Customer and/or source of financing to (i) stop doing business with or through the Company or in any way interfere with
    the relationship between such Company Customer and/or source of financing and the Company, or (ii) do business with Consultant or
    any other person, firm, partnership, corporation or other entity that engages in the business of the Company, or (c) engage in any
    business transaction with a Company Customer and/or source of financing. “Company Customer” shall mean any past or current
    customer of the Company (i) with whom Consultant has had direct or indirect contact in the course of Consultant’s employment
    with the Company, or (ii) about whom Consultant learned Confidential Information.
	 	 	 
	 	(e)	Non-Solicitation
    of Suppliers. The Company’s suppliers are essential to the Company’s business and operation. Consultant acknowledges
    that as a result of Consultant’s relationship with the Company, Consultant will learn the identity of the Company’s suppliers
    and other information about the terms of Consultant’s relationship with the Company, including the compensation and other amounts
    paid by the Company to its suppliers. As a result, Consultant agrees that during the Term and for a period of 12 months following
    the termination of Consultant’s engagement with the Company for any reason, Consultant will not, separately or in association
    with others, directly or indirectly, whether as employee, owner, agent, independent contractor, joint venturer, consultant, advisor
    or in any other individual or representative capacity, (i) solicit, induce or encourage or attempt to solicit, induce or encourage
    any supplier of the Company to cease doing business with the Company, or in any way interfere with the relationship between any such
    supplier and the Company, or (ii) solicit, induce or encourage or attempt to solicit, induce or encourage any supplier of the Company
    to enter into a business relationship with any other business that competes with the business of the Company.

 

    	5

     

    

 

	 	(f)	Non-Competition.
    The Company has valuable, unique, and special assets in the form of its Confidential Information and near-permanent customer
    relationships. Only as a result of Consultant’s relationship with the Company, Consultant will have access to the Confidential
    Information and customer relationships. As such and in order to protect the value of the Confidential Information and near-permanent
    customer relationships, each Consultant agrees that during the Term and for a period of 12 months following the termination of Consultant’s
    engagement with the Company for any reason, Consultant will not, separately or in association with others, directly or indirectly,
    whether as employee, owner, agent, independent contractor, joint venturer, consultant, advisor or in any other individual or representative
    capacity, perform or provide the same or substantially similar work or services to any person or entity that engages in or owns,
    invests in, operates, manages or controls any venture, enterprise or business that directly or indirectly engages in the business
    of the Company anywhere in the world.
	 	 	 
	 	(g)	No
    Disparagement. Consultant hereby agrees that, while Consultant is engaged by the Company and at any time thereafter, Consultant
    will not in any way disparage the Company or its shareholders, directors, officers, employees, representatives or agents, whether
    publicly or privately, orally, in writing, or otherwise, including, without limitation, in communications with any suppliers, clients,
    employees or customers of the Company. Nothing herein, however, will prevent either party from (i) truthfully answering any inquiry
    or request in connection with any judicial or governmental administrative process or which is otherwise required by law or (ii) seeking
    enforcement of such party’s rights and remedies against the other in a court of law, or defending any action brought against
    such party by the other party.
	 	 	 
	 	(h)	Equitable
    Modifications. If any court of competent jurisdiction shall deem any provision in this Section 9 too restrictive, the
    other provisions shall stand, and the court shall modify the unduly restrictive provision (including, without limitation, the length
    of the restricted period(s), the breadth of the restricted geographic territory, or the scope of the restricted activity) to the
    point of greatest restriction permissible by law.
	 	 	 
	 	(i)	Survival
    of Restrictive Covenants. If this Agreement is terminated for any reason, Consultant acknowledges and agrees that these restrictive
    covenants shall survive the termination of this Agreement and Consultant shall continue to be bound by the terms of this Section
    9 as if this Agreement was still in effect.
	 	 	 
	 	(j)	Remedies.
    The Company and Consultant agree that damages will accrue to the Company by reason of Consultant’s failure to observe any
    of these restrictive covenants. Therefore, if the Company shall institute any action or proceeding to enforce such provisions, Consultant
    waives the claim or defense that there is an adequate remedy at law and agrees in any such action or proceeding not to (i) interpose
    the claim or defense that such remedy exists at law, or (ii) require the Company to show that monetary damages cannot be measured
    or to post any bond. Without limiting any other remedies that may be available to the Company, Consultant hereby specifically affirms
    the appropriateness of injunctive or other equitable relief in any such action. Consultant also acknowledges that the remedies afforded
    the Company pursuant to this Section 9(j) are not exclusive, nor shall they preclude the Company from seeking or receiving
    any other relief, including without limitation, any form of monetary or other equitable relief. Upon the reasonable request by the
    Company, Consultant shall provide reasonable assurances and evidence of compliance with the restrictive covenants.

 

10. INDEMNITY.
Consultant agrees to indemnify, defend, and hold the Company and its successors, officers, directors, agents and employees harmless from
any and all actions, causes of action, claims, demands, cost, liabilities, expenses and damages (including attorneys’ fees) arising
out of or related to (i) the activities performed by Consultant incident to or under this Agreement, (ii) a breach by Consultant of this
Agreement, or (iii) Consultant’s failure to comply with any applicable laws.

 

    	6

     

    

 

11. RELATIONSHIP
OF PARTIES. Consultant is an independent contractor of the Company. Nothing in this Agreement shall be construed as creating an employer-employee
relationship, as a guarantee of future engagement or engagement, or as a limitation upon the Company’s’ sole discretion to
terminate this Agreement at any time without cause. Consultant further agrees to be responsible for all of Consultant’s taxes,
social security or similar payments or programs, insurance, and other benefits.

 

12. OTHER
ACTIVITIES. Consultant is free to engage in other independent contracting activities, provided that Consultant does not engage in
any such activities which are inconsistent with or in conflict with any provisions hereof, or that so occupy Consultant’s attention
as to interfere with the proper and efficient performance of the Services by Consultant.

 

 13. MISCELLANEOUS

 

	 	(k)	Attorneys’
    Fees. Should either party hereto, or any heir, personal representative, successor or assign of either party hereto, resort to
    legal proceedings in connection with this Agreement or Consultant’s relationship with the Company, the party or parties prevailing
    in such legal proceedings shall be entitled, in addition to such other relief as may be granted, to recover its or their reasonable
    attorneys’ fees and costs in such legal proceedings from the non-prevailing party or parties.
	 	 	 
	 	(l)	Governing
    Law; Venue. The laws of the State of Illinois (irrespective of its choice of law principles) shall govern all matters arising
    out of or relating to this Agreement and the transactions contemplated hereby, including, without limitation, its interpretation,
    construction, performance, and enforcement. All actions or proceedings in any way, manner or respect, arising out of or from or related
    to this Agreement shall be litigated only in courts having situs in Chicago, Illinois. Each party to this Agreement hereby consents
    and submits to the exclusive jurisdiction of any court sitting in Illinois and its appellate courts for the purposes of all legal
    actions and proceedings arising out of or relating to this Agreement, and waives any right such party may have to transfer the venue
    of any such action or proceeding.
	 	 	 
	 	(m)	Entire
    Agreement. This Agreement contains the entire agreement and understanding between the parties hereto and supersedes any prior
    or contemporaneous written or oral agreements, representations and warranties between them respecting the subject matter hereof.
    This Agreement may be amended only by a writing signed by Consultant and by a duly authorized representative of the Company. No failure
    or neglect of either party hereto in any instance to exercise any right, power or privilege hereunder or under law shall constitute
    a waiver of any other right, power or privilege or of the same right, power or privilege in any other instance. All waivers by either
    party hereto must be contained in a written instrument signed by the party to be charged and, in the case of the Company, by an officer
    of the Company or other person duly authorized by the Company.
	 	 	 
	 	(n)	Precedence
    of Exhibits. If there is any contradiction between the Agreement and any Exhibits (i.e. “Statements of Work”) attached
    to the Agreement, then the terms set forth in the latest Exhibit (“Statement of Work”) will take precedence.
	 	 	 
	 	(o)	Severability.
    If any term, provision, covenant or condition of this Agreement, or the application thereof to any person, place or circumstance,
    shall be held to be invalid, unenforceable or void, the remainder of this Agreement and such term, provision, covenant or condition
    as applied to other persons, places and circumstances shall remain in full force and effect.
	 	 	 
	 	(p)	Construction.
    The headings and captions of this Agreement are provided for convenience only and are intended to have no effect in construing or
    interpreting this Agreement. The language in all parts of this Agreement shall be in all cases construed according to its fair meaning
    and not strictly for or against either party.
	 	 	 
	 	(q)	Rights
    Cumulative. The rights and remedies provided by this Agreement are cumulative, and the exercise of any right or remedy by either
    party hereto (or by its successor), whether pursuant to this Agreement, to any other agreement, or to law, shall not preclude or
    waive its right to exercise any or all other rights and remedies.

 

    	7

     

    

 

	 	(r)	Remedy
    for Breach. The parties hereto agree that, in the event of breach or threatened breach of any covenants of Consultant, the damage
    or imminent damage to the value and the goodwill of the Company’s business shall be inestimable, and that therefore any remedy
    at law or in damages shall be inadequate. Accordingly, the parties hereto agree that the Company shall be entitled to seek injunctive
    relief against Consultant in the event of any breach or threatened breach of any of such provisions by Consultant, in addition to
    any other relief (including damages) available to the Company under this Agreement or under law.
	 	 	 
	 	(s)	Notices.
    Any notice, request, consent or approval required or permitted to be given under this Agreement or pursuant to law shall be sufficient
    if in writing, and if and when sent by e-mail (as a scan or PDF) to email addresses set forth in the Initial SOW (“E-mails”),
    fax, or personal delivery, to Consultant’s address, or to the Company’s principal office, as the case may be.
	 	 	 
	 	(t)	Immunity.
    Consultant shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade
    secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to
    an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint
    or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Accordingly, Consultant has the right
    to disclose in confidence trade secrets to Federal, State, and local government officials, or to an attorney, for the sole purpose
    of reporting or investigating a suspected violation of law by Company. Consultant also has the right to disclose trade secrets in
    a document filed in a lawsuit or other proceeding, but only if the filing is made under seal and protected from public disclosure.
    Nothing in this Agreement is intended to conflict with 18 U.S.C. § 1833(b) or create liability for disclosures of trade secrets
    that are expressly allowed by 18 U.S.C. § 1833(b).
	 	 	 
	 	(u)	Jury
    Trial Waiver. EACH PARTY, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY
    JURY AS TO ANY ISSUE RELATING HERETO IN ANY ACTION, PROCEEDING, OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY
    OTHER MATTER INVOLVING THE PARTIES HERETO.

 

[Signature
page(s) follow(s).]

 

    	8

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Independent Contractor Agreement as of the day and year first written above.

 

	COMPANY:
    	 	CONSULTANT:
	 	 	 	 	 
	By:
    	/s/
    Steven Morris	 	By:
    	/s/
    Ravi Birla
	 	 	 	 	 
	Name:
    	Steven
    Morris	 	Name:
    	Ravi
    Birla
	 	 	 	 	 
	Title:
    	CEO	 	 	 

 

    	9

     

    

 

EXHIBIT
A

 

Statement
of Work (“SOW”) dated December 29, 2021 (the “SOW Effective Date”)

 

	Consultant’s
    Name: 	Ravi
    Birla
	Consultant’s
    Address:	5215
    Harvest Bend Court
	 	Sugar
    Land, TX 77479

 

 1. SERVICES.

 

Consultant
shall perform the following services (“Services”) to Company in accordance with the terms and conditions of this SOW and
the Service Agreement (the “Agreement”) to it is attached:

 

	 	(a)	implement,
    promote and oversee creation, development and maintenance of the Company’s intellectual property (the “Company’s
    IP”);
	 	(b)	oversee
    personnel, scheduling, research strategy, research planning, and research execution;
	 	(c)	implement,
    promote and oversee best practices and safety protocols for all activities at the Company’s laboratory (the “Lab”),
    including, without limitation, reporting of all activities at the Lab and the maintenance of all records of activities at the Lab;
	 	(d)	oversee
    all scale-up activities of the Lab;
	 	(e)	oversee
    (and serve as the point person for) all research activities and ensure research and personnel productivity;
	 	(f)	provide
    training to all Lab personnel such that they can perform their expected duties;
	 	(g)	prepare
    reports and other communications for the Company’s chief executive officer (“CEO”) or the Company’s board
    of directors (the “Board”); and
	 	(h)	perform
    any other duties or tasks, as reasonably requested by the CEO or the Board.

 

The
Consultant hereby agrees to provide such Services to the Company and perform all other duties and responsibilities in the best interests
of the Company, in a professional, workmanlike manner and in accordance with all Company policies, including, without limitation, the
Company’s data security policy. In connection with the Services, Consultant shall (i) be available for Zoom or other calls as needed,
(ii) be available for and conduct formal presentations to potential investors or other parties requested by Company, (iii) prepare and
present any requested strategy or operational related documents or materials, including presentation decks, as may be requested, (iv)
provide tours and presentations of the Lab, as requested, (v) participate as requested in road show activities updates, and presentations
as may be requested; and (vi) be present in lab no less than 3 days per week.

 

 2. COMPENSATION

 

For
the services rendered by the Consultant as required by this Agreement the Company will provide compensation (the “Compensation”)
to the Consultant of $8,000 per calendar month, payable on last day of month worked. Upon execution of this Agreement, Consultant shall
receive 10,000 shares of non-voting common stock of the Company, which such shares were previously forfeited by Consultant. In addition,
in the Consultant satisfies the Equity Conditions (as defined below), as determined by the Board in its sole by reasonable discretion,
the Consultant shall receive from the Company the Previously Forfeited Option Compensation (as defined below), which such options were
previously forfeited by Consultant. For the avoidance of doubt, Consultant acknowledges that he previously forfeited all equity interests
in the Company, including, without limitation, (a) the 10,000 shares of non-voting common stock of the Company that will be granted to
him by the Company upon execution of this Agreement and (b) the Previously Forfeited Option Compensation.

 

For
the purposes of this Agreement, the following terms shall have the following meanings:

 

	-	“Equity
    Conditions” shall mean (a) completion of a printed mini-heart that viable for two or more weeks, (b) a functional, visible,
    normal electrocardiogram that can be visually and audibly displayed in a manner approved by the Board, and (c) filing of two new
    patent applications on or before March 31, 2022; and
	-	“Previously
    Forfeited Option Compensation” shall mean options to purchase 135,000 shares of non-voting common stock of the Company.

 

    	10

     

    

 

 3. SECTION 3 NOTICE REQUIREMENTS

 

Calendar
days’ notice required: 30 Days

 

Consultant
shall work with Company’s Representatives: Steven Morris, CEO or any other individuals as directed by CEO or the Board.

 

E-mails

 

Consultant:
rkbirla2@gmail.com or rbirla@biolife4d.com.

 

Company:
smorris@biolife4d.com with a copy to jhechtma@hmblaw.com.

 

[Signature
page(s) follow(s).]

 

    	11

     

    

 

Exhibit
B

 

Prior
Inventions

 

	TO:	BioLife4D
    Corporation
	 	 
	FROM:	Ravi
    Birla
	 	 
	DATE:	12/29/2021
	 	 
	SUBJECT:	Previous
    Inventions

 

1. Except
as listed in Section 2 below, the following is a complete list of all inventions or improvements relevant to the subject matter of my
engagement by BioLife4D Corporation (the “Company”) that have been made or conceived or first reduced to practice
by me alone or jointly with others prior to my engagement by the Company:

 

	 	☐	No
    inventions or improvements.
	 	 	 
	 	☐	See
    below:
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	☐	Additional
    sheets attached.

 

2. Due
to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above with respect to inventions or improvements
generally listed below, the proprietary rights and duty of confidentiality with respect to which I owe to the following party(ies):

 

	 	Invention
    or Improvement	 	Party(ies)	 	Relationship
	 	 	 	 	 	 
	1.	 	 	 	 	 
	 	 	 	 	 	 
	2.	 	 	 	 	 
	 	 	 	 	 	 
	3.	 	 	 	 	 
	 	 	 	 	 	 
	☐	Additional
    sheets attached.	 	 	 	 

 

    	12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]